Kiniksa Pharmaceuticals股票讨论区

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

$Kiniksa Pharmaceuticals(KNSA.US)$2021年首次产生营收0.39亿，营业利润和净利润则是连续亏损5年。2022前三季度营收持续增长，Q3达到了1亿，营业利润在Q3也产生了0.46亿的利润，净利润则由于1.8亿的所得税返还达到了2.2亿。
目前市盈率TTM 7.2，如果刨除所得税返还影响，市盈率TTM其实还是负的。
由于只有一个季度的盈利数据，无法判断持续盈利能力，继续观察。

Okie, let’s look at the market. As I am very busy recently, my post is a lot slower. But, I am still monitoring the market closely. Today, the posts will be long, and the contents are as below:
i) Current market- $SPDR 标普500指数ETF(SPY.US)$
ii) Oil price
iii) My trade based on stage analysis
i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...

$Kiniksa Pharmaceuticals(KNSA.US)$ buy more for TP $30